1. Home
  2. GIB vs RDY Comparison

GIB vs RDY Comparison

Compare GIB & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CGI Inc.

GIB

CGI Inc.

HOLD

Current Price

$66.43

Market Cap

12.8B

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$11.79

Market Cap

11.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIB
RDY
Founded
1976
1984
Country
Canada
India
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
11.8B
IPO Year
1999
2001

Fundamental Metrics

Financial Performance
Metric
GIB
RDY
Price
$66.43
$11.79
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$112.00
$16.90
AVG Volume (30 Days)
393.1K
3.1M
Earning Date
04-29-2026
05-12-2026
Dividend Yield
0.70%
0.52%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$8.33
$7.72
Revenue Next Year
$2.96
$3.50
P/E Ratio
$13.59
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$59.63
$11.36
52 Week High
$103.04
$15.67

Technical Indicators

Market Signals
Indicator
GIB
RDY
Relative Strength Index (RSI) 52.10 32.74
Support Level $60.78 N/A
Resistance Level $69.13 $13.96
Average True Range (ATR) 1.70 0.39
MACD -0.06 -0.21
Stochastic Oscillator 66.37 15.77

Price Performance

Historical Comparison
GIB
RDY

About GIB CGI Inc.

CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: